Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - bendroflumethiazide - tablet - 5 milligram(s) - bendroflumethiazide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

brillpharma (ireland) limited - bendroflumethiazide - tablet - 2.5 milligram(s) - bendroflumethiazide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

brillpharma (ireland) limited - bendroflumethiazide - tablet - 5 milligram(s) - bendroflumethiazide

Israeli - Kiingereza - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israeli - Kiingereza - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israeli - Kiingereza - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israeli - Kiingereza - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Kanada - Kiingereza - Health Canada

accord healthcare inc - bendamustine hydrochloride - powder for solution - 25mg - bendamustine hydrochloride 25mg - antineoplastic agents

Kanada - Kiingereza - Health Canada

accord healthcare inc - bendamustine hydrochloride - powder for solution - 100mg - bendamustine hydrochloride 100mg - antineoplastic agents

Kanada - Kiingereza - Health Canada

natco pharma (canada) inc - bendamustine hydrochloride - powder for solution - 25mg - bendamustine hydrochloride 25mg - antineoplastic agents